EMERYVILLE, Calif. — Biotech firm Vivani Medical is developing a miniature, subdermal drug implant designed to deliver semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, to help patients sustain long-term weight loss. The California-based company aims to address a critical flaw in current obesity treatments: the high rate of patient non-compliance and subsequent weight rebound associated with weekly self-injections.
The investigational device, currently known as NPM-115, leverages proprietary technology to slowly release medication over a six-month period. By shifting the delivery method from a weekly self-administered needle to a twice-yearly clinical procedure, developers hope to transform how chronic obesity is managed globally.
The Challenge of Weight Rebound and Compliance
The rise of GLP-1 receptor agonists has revolutionized metabolic medicine, offering unprecedented weight loss results. However, clinical data shows that a significant portion of patients struggle to maintain the regimen over the long term. A study published in the journal Obesity found that up to two-thirds of patients stop taking GLP-1 medications within the first year due to side effects, cost, or injection fatigue.
When patients discontinue these medications, the consequences are swift. Clinical trials, including Novo Nordisk’s STEP-1 trial extension, demonstrate that patients typically regain two-thirds of their lost weight within a year of stopping semaglutide. This “rebound effect” underscores the need for a continuous, long-term maintenance strategy that does not rely on daily or weekly patient adherence.
How the Subdermal Implant Works
Vivani’s solution is a matchstick-sized implant utilizing their proprietary NanoPortal technology. The tiny device is inserted just beneath the skin, typically in the upper arm, during a simple, in-office outpatient procedure. Once in place, it slowly and steadily diffuses semaglutide directly into the bloodstream at a controlled rate.
By bypassing the digestive system and avoiding the rapid peaks and troughs associated with weekly injections, the implant could offer a more stable therapeutic window. Vivani engineers design the system to provide a continuous dose for up to six months, after which the device is removed and replaced.
Preclinical data released by the company has yielded promising results. In animal studies, the implant achieved steady-state drug levels and demonstrated weight loss efficacy comparable to active injections, while showing a potentially improved tolerability profile.
Expert Perspectives on Dosing and Tolerability
Medical experts suggest that a continuous-release system could solve more than just compliance issues. Gastrointestinal side effects, such as nausea, vomiting, and diarrhea, are the primary reasons patients abandon GLP-1 therapies. These side effects are often triggered by the rapid spike in drug concentration that occurs shortly after a weekly injection.
“A steady-state delivery system could theoretically mitigate the peak-dose side effects that plague current GLP-1 therapies,” says Dr. Evelyn Vance, an endocrinologist specializing in obesity management. “If we can smooth out the delivery curve, we may improve patient tolerance and keep more individuals on their therapy safely.”
Furthermore, the implant format removes the psychological barrier of self-injection. For patients with needle phobias or those who struggle with the logistics of storing refrigerated pens, a twice-yearly clinic visit offers a highly appealing alternative.
Market Implications and the Competitive Landscape
The global market for weight-loss medications is projected to reach $100 billion by 2030, according to industry analysts at Goldman Sachs. While Novo Nordisk and Eli Lilly currently dominate the landscape, the introduction of alternative delivery mechanisms could disrupt this duopoly. Vivani is not alone in exploring alternative delivery; several pharmaceutical giants are racing to develop oral GLP-1 pills and longer-lasting formulations.
However, an implantable option represents a unique niche. It appeals particularly to healthcare payers and insurers, who are increasingly concerned about paying for expensive medications that patients do not take consistently. A guaranteed six-month adherence rate could make the implant a highly cost-effective option for insurance coverage.
What to Watch Next
The path to regulatory approval remains a multi-year journey. Vivani Medical is currently advancing its preclinical programs toward human clinical trials. The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical trials evaluating safety, tolerability, and efficacy in humans.
Industry watchers will be closely monitoring the first-in-human data, particularly regarding the ease of insertion and removal, local tissue tolerability, and whether the implant can match the weight-loss efficacy of high-dose weekly injections. If successful, this tiny device could shift the paradigm of obesity care from active, weekly intervention to passive, long-term maintenance.
